AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Amazon Explores AI Content Marketplace With Media Publishers 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
HENDERSON, Nev., Jan. 09, 2018 -- United Health Products, Inc. (UHP) (OTCPK:UEEC), manufacturer and marketer of HemoStyp, a patented hemostatic gauze for the healthcare and wound care sectors, today announced that the key patent underlying HemoStyp has been extended until 2029.
Separately, the company announced that it is continuing its work in the FDA’s CtQ Pilot program to have HemoStyp approved for Class III internal surgical use, as well as maintaining its Class II submission for expanded indication.
About United Health Products, Inc.
United Health Products (UHP) develops, manufactures, and markets patented hemostatic gauze, for the healthcare and wound care sectors. The product, HemoStyp®, is derived from regenerated oxidized cellulose, which is all natural and designed to absorb exudate/drainage from superficial wounds and helps control bleeding. UHP is focused on identifying new markets and applications for its products, and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact:
United Health Products, Inc.
877-358-3444
IR Contact:
PAN Consultants Ltd.
Philippe Niemetz
212 -344 - 6464
